Daniel J. Lippis, CVP, TAVR at Edwards Lifesciences Corp (NYSE:EW), filed a Form 4 on November 10, 2026, reporting the exercise of 619 employee stock options and the same-day sale of 619 shares of common stock.

Key Highlights

  • Option exercise: Lippis exercised 619 employee stock options on November 10, 2026, at an exercise price of $72.68 per share (transaction code M).
  • Share sale: 619 shares of common stock were sold on November 10, 2026, at $104.25 per share (transaction code S).
  • Post-transaction ownership: Following these transactions, Lippis directly held 40,033.9103 shares of common stock.
  • Remaining options: 2,476 employee stock options remain beneficially owned directly, with an expiration date of May 6, 2027.
  • 10b5-1 plan: Both transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Lippis on February 13, 2026.

Lippis Option Exercise and Sale Details for Edwards Lifesciences

According to the Form 4 filed with the SEC on November 10, 2026, Daniel J. Lippis, who serves as CVP, TAVR at Edwards Lifesciences Corp (NYSE:EW), reported two transactions in the company's common stock. First, Lippis exercised 619 employee stock options at a conversion price of $72.68 per share. Those options were originally exercisable as of May 7, 2021, and carry an expiration date of May 6, 2027.

On the same date, the filing disclosed that Lippis disposed of 619 shares of common stock at a sale price of $104.25 per share. Following both the acquisition via exercise and the subsequent disposal, his direct beneficial ownership in common stock stood at 40,033.9103 shares, according to the filing. His remaining directly held employee stock options total 2,476, with a stated derivative security price of $0.0000.

The filing notes that both the exercise and the sale "were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026." The form was signed by Linda J. Park as Attorney-in-Fact on November 10, 2026. The filing also states: "This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person."

What Was Disclosed

Daniel J. Lippis, CVP, TAVR at Edwards Lifesciences Corp, reported a same-day option exercise of 619 shares at $72.68 and a sale of 619 shares at $104.25 on November 10, 2026, both conducted under a pre-established Rule 10b5-1 trading plan.